N2OFF shares update from CEO Silberman

N2OFF (NITO), following the completion of its acquisition of MitoCareX Bio, shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman. “It is with great enthusiasm that we share with you the progress and vision of MitoCareX Bio, a pioneering biotechnology company powered by MITOLINE, MitoCareX’s proprietary algorithm designed to enable reliable 3D modeling of mitochondrial transport proteins… Over the past year, MitoCareX has achieved meaningful scientific and operational milestones. We have continuously identified promising hit compounds with measurable biological activity, validating the predictive ability of our MITOLINE-based modeling approach… In parallel, we are exploring strategic collaborations and potential licensing agreements to expand MITOLINE’s applications beyond our core programs… Looking beyond 2026, our long-term strategy aims to focus on preparing for IND-enabling studies, a key inflection point that will transition MitoCareX toward clinical readiness, while in parallel we aim to establish MITOLINE as a scalable discovery engine… Our differentiated focus on the mitochondrial SLC25 family – combined with the potential scalability of MITOLINE – positions us uniquely within the next generation of drug discovery companies.”